生物活性因子應用於眼表疾病治療之新商業模式探討

Abstract

乾眼症儼然已成為現代文明病，近年來隨著生活型態改變、生活仰賴3C產品、加上雷射手術的後遺症，罹患乾眼症的年齡層逐步降低，再加上人口高齡化的趨勢，罹患乾眼症患者人數日益增加。 乾眼症治療市場持續增長，然而至今乾眼症尚無有效治療方式，本研究希望透過文獻分析與商業模式探討，以探究已在骨科、運動醫學廣泛使用的再生醫學領 “自體生物活性因子” 用於乾眼症治療之可行性及導入自動化系統的商業模式。

Dry eye disease (DED) has become a public health issue recently. Since life style change, increasing and constant use of digital devices, increasing eye LASIK surgery, prevalence has increasing rapidly both in older adults and younger populations. With the increasing market in Dry eye disease, it is important to establish effective treatments. This study intends to figure out the feasibility of using Bioactive Factors in Ocular surface disease treatment, and the business model to introducing an automatic autologous bioactive factors collection device into market.